# Fitting_Lin_QSP

This repository will hold the revised version of our Lin et al 2022 QSP model reproduction as well as sources of data used to re-fit the model.

## Empirical Data Analysis

### SUVR Reduction Data

The repository includes empirical data from the PRIME study showing SUVR (Standardized Uptake Value Ratio) changes from baseline for different doses of Aducanumab.

#### Data Source
- **File**: `data/SUVR/SUVR_PRIME.xlsx`
- **Study**: PRIME clinical trial
- **Reference**: [Sevigny et al. (2016)](https://www.nature.com/articles/nature19323)
- **Data Source**: Extended Table 1
- **Measure**: SUVR change from baseline
- **Conditions**: Placebo, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg
- **Time Points**: 6 months (0.5 years) and 1 year
- **Units**: Dimensionless SUVR values



![SUVR Reduction from PRIME Study](figures/empirical_data/PRIME_SUVR_Reduction.png)

*Figure 1: SUVR change from baseline over time for different Aducanumab doses. Error bars represent 95% confidence intervals. Data from Extended Table 1 in Sevigny et al. (2016), PRIME clinical trial.*

![SUVR Reduction from EMERGE and ENGAGE Studies](figures/empirical_data/EMERGE_ENGAGE_SUVR_Reduction.png)

*Figure 2: SUVR change from baseline over time for EMERGE and ENGAGE Phase 3 clinical trials. Data shows placebo, low-dose, and high-dose Aducanumab treatment groups. Sample sizes (n) are displayed below each data point. Data from [Budd Haeberlein et al. (2022)](https://doi.org/10.14283/jpad.2022.30), EMERGE and ENGAGE clinical trials.*

![SUVR Reduction from Lecanemab Phase 2b Study](figures/empirical_data/LECANEMAB_Phase2b_SUVR_Reduction.png)

*Figure 3: SUVR change from baseline over time for Lecanemab Phase 2b clinical trial. Data shows placebo and various dosing regimens (bi-weekly and monthly). Data from Swanson et al. (2021), Phase 2b clinical trial.*

![SUVR Reduction from Lecanemab Phase 3 Study](figures/empirical_data/LECANEMAB_Phase3_SUVR_Reduction.png)

*Figure 4: SUVR change from baseline over time for Lecanemab Phase 3 clinical trial. Data shows placebo and Lecanemab treatment groups. Data from van Dyck et al. (2022), Phase 3 clinical trial.* 
